|
|
Volumn 334, Issue 7589, 2007, Pages 326-
|
|
Early termination of drug trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIARRHYTHMIC AGENT;
ATORVASTATIN;
CLARITHROMYCIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
TORCETRAPIB;
QUINOLINE DERIVATIVE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
DRUG APPROVAL;
DRUG DOSE COMPARISON;
DRUG INDUSTRY;
DRUG MONITORING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SCREENING;
DRUG WITHDRAWAL;
EDITORIAL;
HUMAN;
ISCHEMIC HEART DISEASE;
MONOTHERAPY;
MORTALITY;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SECONDARY PREVENTION;
UNSPECIFIED SIDE EFFECT;
BLOOD;
DRUG SURVEILLANCE PROGRAM;
METHODOLOGY;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
CHOLESTEROL, HDL;
DRUG INDUSTRY;
QUINOLINES;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 33847104726
PISSN: 09598146
EISSN: None
Source Type: Journal
DOI: 10.1136/bmj.39113.534919.80 Document Type: Editorial |
|
Times cited : (10)
|
|
References (0)
|
